Abstract: BM-13505 is a new type of thromboxane receptor antagonist developed first abroad and synthesized in our school, with a modifed method recently. The results of our study showed that the occlusion time of carotid artery in experimental thrombosis rats was prolonged by BM-13505, 0.45 and 0.23 mg/kg iv (P<0.00 1 and <0.01 respectively). BM-13505 2 mg/kg iv effectively prevented the cerebral thrombosis caused by AA 4 mg/kg in rats (P<0.01) BM-13505 10 mg/kg ip prevented the AA-induced pulmonary thrombosis in mice (P<0.01). Tail bleeding time of mice was prolonged by this dru.BM-13505 significantly inhibited the AA-induced rabbit platelet aggregation, with an IC50 of 0.17 μmol/L; ADP-and collagen-induced aggregations were not affected.TXB2 level in platelets and that in mice plasma were decreased by BM-13505, but cAMP level in platelets was not affected. BM-13505 may be possibly developed into a useful anti-platelet and anti-thrombotic drug.

Key words: BM-13505, Thrombosis, Platelet aggregation, Thromboxane receptor antagonist